Life Sciences Daily Summary
Life Sciences Daily Summary: What Happened on October 26, 2026
Pathos AI raises $237 million to advance cancer programs
Bristol Myers Squibb led the Series E. Pathos plans to expand its Foundry platform and advance four clinical cancer programs.
Today in brief
Pathos AI secured $237 million in a Series E led by Bristol Myers Squibb, putting its post-financing valuation at about $3 billion.1 The company plans to use the funding for its Foundry platform and four clinical cancer programs.1
Pathos AI secures $237 million for oncology programs
Pathos AI raised $237 million in a Series E financing led by Bristol Myers Squibb, with existing investors also contributing.1 The round valued Pathos at about $3 billion post-money.1
Pathos said it plans to expand Foundry and advance four active clinical cancer programs.1 The company said Foundry evaluates biological, clinical, genomic and competitor information to guide drug-program decisions.1 Pathos said it is preparing JSKN016 for registrational trials and developing pocenbrodib for prostate cancer and multiple myeloma.1